BioCentury | Jun 21, 2019
Emerging Company Profile

Arcutis: Reformulating dermatology

Arcutis Inc. is using its founders’ topical reformulation expertise to develop safer and less expensive therapeutics against known targets to treat dermatology patients who aren’t eligible for biologics. Frazier Healthcare launched the company in 2016...
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
BC Innovations | Sep 20, 2018
Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Mouse studies suggest ablating meningeal lymphatic vessels with Visudyne verteporfin could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, injection into the cisterna magna of Visudyne...
BioCentury | Aug 3, 2018
Finance

Earnings on deck

Earnings on deck At least 8 profitable biotechs and pharmas are slated to report earnings this week. (A) Formerly Valeant Pharmaceuticals International Inc. Company Date Pre/post mkt 2Q18 EPS est 2Q17 EPS Expected chg Bausch...
BioCentury | Jul 13, 2018
Finance

Pause for politics

The near record-setting pace of 1H18 capital markets activity isn’t likely to be replicated this half, but that won’t be because of changes to sector fundamentals. Instead, it’s likely the consequence of macroeconomic and geopolitical...
BioCentury | Jun 30, 2018
Finance

Hidden in the rough

Judicious stock picking was especially important in the second quarter, as 57% of global biotech stocks saw their equity values decline. Volatility continued to roil global markets during the period and additional uncertainty looms with...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
BC Week In Review | Jun 22, 2018
Clinical News

Valeant receives complete response letter for psoriasis candidate

The Ortho Dermatologics unit of Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) said it received a complete response letter from FDA to an NDA for Duobrii (IDP-118) to treat plaque psoriasis. According to Valeant, FDA had...
BC Extra | Jun 18, 2018
Company News

Valeant slides on psoriasis delay

Ortho Dermatologics said it received a complete response letter from FDA to an NDA for Duobrii (IDP-118) to treat plaque psoriasis. Ortho parent Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) slid $3.32 (12%) to $23.54 on...
BC Innovations | May 11, 2018
Finance

Amplifying oligos

The last five years have seen a steady stream of preclinical deals for antisense, siRNA and mRNA therapies that suggests pharmas are taking the modalities seriously as alternatives to traditional small molecules and antibodies. But...
Items per page:
1 - 10 of 884
BioCentury | Jun 21, 2019
Emerging Company Profile

Arcutis: Reformulating dermatology

Arcutis Inc. is using its founders’ topical reformulation expertise to develop safer and less expensive therapeutics against known targets to treat dermatology patients who aren’t eligible for biologics. Frazier Healthcare launched the company in 2016...
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
BC Innovations | Sep 20, 2018
Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Mouse studies suggest ablating meningeal lymphatic vessels with Visudyne verteporfin could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, injection into the cisterna magna of Visudyne...
BioCentury | Aug 3, 2018
Finance

Earnings on deck

Earnings on deck At least 8 profitable biotechs and pharmas are slated to report earnings this week. (A) Formerly Valeant Pharmaceuticals International Inc. Company Date Pre/post mkt 2Q18 EPS est 2Q17 EPS Expected chg Bausch...
BioCentury | Jul 13, 2018
Finance

Pause for politics

The near record-setting pace of 1H18 capital markets activity isn’t likely to be replicated this half, but that won’t be because of changes to sector fundamentals. Instead, it’s likely the consequence of macroeconomic and geopolitical...
BioCentury | Jun 30, 2018
Finance

Hidden in the rough

Judicious stock picking was especially important in the second quarter, as 57% of global biotech stocks saw their equity values decline. Volatility continued to roil global markets during the period and additional uncertainty looms with...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
BC Week In Review | Jun 22, 2018
Clinical News

Valeant receives complete response letter for psoriasis candidate

The Ortho Dermatologics unit of Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) said it received a complete response letter from FDA to an NDA for Duobrii (IDP-118) to treat plaque psoriasis. According to Valeant, FDA had...
BC Extra | Jun 18, 2018
Company News

Valeant slides on psoriasis delay

Ortho Dermatologics said it received a complete response letter from FDA to an NDA for Duobrii (IDP-118) to treat plaque psoriasis. Ortho parent Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) slid $3.32 (12%) to $23.54 on...
BC Innovations | May 11, 2018
Finance

Amplifying oligos

The last five years have seen a steady stream of preclinical deals for antisense, siRNA and mRNA therapies that suggests pharmas are taking the modalities seriously as alternatives to traditional small molecules and antibodies. But...
Items per page:
1 - 10 of 884